Doxorubicin Hydrochloride

Doxorubicin Hydrochloride is a cytotoxic anthracycline antibiotic. It binds to DNA and inhibits nucleic acid synthesis, and interacts with topoisomerase II to form DNA-cleavable complexes.

• Cancer

Doxorubicin is a cytotoxic anthracycline antibiotic. Its cytotoxic action results from binding to DNA and inhibition of nucleic acid synthesis. It also interacts with topoisomerase II to form DNA-cleavable complexes.

Doxorubicin binds to DNA and inhibits nucleic acid synthesis. It interacts with topoisomerase II to form DNA-cleavable complexes, which is an important mechanism of its cytocidal activity.

Adult Dose (IV):

• Kaposi's Sarcoma: 20 mg/m² q3Weeks
• Ovarian Cancer: 50 mg/m² q4Weeks
• Multiple Myeloma: 30 mg/m² (with bortezomib)
• Metastatic breast cancer: 60-75 mg/m² q3Weeks

Hepatic Dose: Bilirubin 1.2-3 mg/dL: 50% dose; 3.1-5 mg/dL: 25% dose; Severe impairment: Contraindicated.

Administered as intravenous injection or infusion by a doctor or nurse. Kindly do not self administer.

If you miss a dose of Doxorubicin Hydrochloride, please consult your doctor.

Common Side Effects (>10%):

• Alopecia
• Nausea and vomiting

Other Side Effects:

• Cardiomyopathy and arrhythmias
• Secondary malignancies
• Extravasation and tissue necrosis
• Severe myelosuppression
• Tumor lysis syndrome

• Can cause fetal harm during pregnancy.
• Discontinue if signs of cardiomyopathy develop.
• Dose reduction needed in hepatic impairment.
• Inform doctor if signs of infection (fever, sore throat, rash) occur.

• Severe myocardial insufficiency
• Recent (within 4-6 weeks) myocardial infarction
• Severe drug-induced myelosuppression
• Severe hepatic impairment (Child Pugh C or bilirubin >5 mg/dL)
• Severe hypersensitivity

Doxorubicin is a substrate of CYP3A4, CYP2D6 and P-gp. Avoid concurrent use with inhibitors and inducers of CYP3A4, CYP2D6 or P-gp. Increased cardiac dysfunction risk with trastuzumab. Paclitaxel increases doxorubicin plasma concentrations.

It is not known whether it is safe to consume alcohol with Doxorubicin Hydrochloride. Please consult your doctor.

Pregnancy Category D. Can cause fetal harm. Use effective contraception during and for 6 months after treatment.

Evidence suggests doxorubicin is excreted in human milk. Decision to discontinue nursing or the drug should be made.

Pediatric dosage should be determined by a physician. Long-term periodic cardiovascular monitoring recommended.

No overall differences in safety and effectiveness found compared with younger patients.

Renal impairment: Safe in kidney disease. No dose adjustment needed.

Hepatic impairment: Use with caution. Dose adjustment may be needed. Not recommended in severe liver disease.

Overdose: 250 mg and 500 mg doses have proven fatal. May cause acute myocardial degeneration and severe myelosuppression.

Store in a dry place at 2°-8°C. Protect from light and do not freeze. Keep out of reach of children.

Doxorubicin Hydrochloride